June 2015 To the Shareholders of Point Capital Inc.: Point Capital has gotten off to an incredible start in 2015, and our management team is once again pleased to share with you some of our advances since our last shareh

To the Shareholders of Point Capital Inc.:

Point Capital has gotten off to an incredible

start in 2015, and our management team is once again pleased to share with you some of our advances since our last shareholder

letter. We are very excited about the prospects of our portfolio of companies as we head into the second half of 2015. A brief

synopsis of some of the most recent companies and type of investments are included for your review.

Our mission and management have remained unchanged

since our last shareholder letter, and we continue to strive in our core competencies. We continue our efforts to identify and

evaluate investment opportunities in emerging growth companies that we believe will enable Point Capital to achieve significant

returns on deployed capital. As of March 31, 2015 our company's investments at fair value were 47.88% of total assets; cash

and cash equivalents were 44.54%; and other current assets were 7.57%. We hope that with our extensive business relationships

and capital markets expertise we can continue so that we can achieve superior results. As always, we strive to make the right

investment decisions and surround ourselves with the most seasoned business professionals who can bring valuable insight to our

decision making process and provide a strong knowledge base to help our portfolio companies grow. Our independent directors, Van

Parker, Leonard Schiller and Joel Stone continue to provide great guidance.

As we forge ahead into 2015, we are excited

about the future prospects of our company. We are in various stages of due diligence in examining future investment opportunities.

We are working diligently to strategically maximize the value of our company for the years to come, and most importantly for the

benefit of our stockholders. We are hopeful that our work in 2014 and some of our recent 2015 investments will lead to several

liquidity events by the latter part of this year. We would like to thank each and every one of you for your support as we continue

to work diligently to maximize the value of our company in the years to come for the benefit of our shareholders.

The Company encourages shareholders to not

rely solely on this shareholder update and to refer to the Company's Quarterly Report on Form 10-Q for full disclosure relating

to the first quarter financial report, as well as all the Company's filings with the United States Securities and Exchange

Commission, which can be found at www.sec.gov.

Grand Avenue, 5 Patriot Center, Fl. 2 Englewood, NJ 07631 O: (201)408-5126 F: (201)408.5125

This letter contains forward-looking statements,

particularly as related to, among other things, the Company's performance and future operations. Actual results could differ

materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking

statements are based on current expectations, involve known and unknown risks, reliance on third parties, and other factors that

may cause our actual results, performance or achievements, or developments in its industry, to differ materially from the anticipated

results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual

results to differ materially from anticipated results include risks and uncertainties related to our ability to generate any sales

or positive revenues in the markets described above, general economic conditions and other factors that are detailed in Point

Capital's documents filed with the Securities and Exchange Commission. Statements made herein are as of the date of this

letter and should not be relied upon as of any subsequent date. The Company cautions readers not to place undue reliance on such

statements. Point Capital, Inc. does not undertake, and specifically disclaims any obligation, to update any forward-looking statements

to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. Actual results may

differ materially from our expectations and estimates.

Grand Avenue, 5 Patriot Center, Fl. 2 Englewood, NJ 07631 O: (201)408-5126 F: (201)408.5125

Below is a partial list of some opportunities

in which Point Capital has invested for the periods of 2014-2015. For the complete list of all Investments since inception, please

review the March 31, 2015 Form 10-Q filed with the SEC www.sec.gov.

Ruthigen, Inc. (RTGN) On March 21,

2014, we completed an investment in shares of Common Stock and Warrants. Ruthigen, Inc., a Nasdaq listed company, focuses on the

discovery, development, and commercialization of pharmaceutical-grade hypochlorous acid based therapeutics to prevent and treat

infection in invasive applications.

Orbital Tracking Corp. (TRKK) On October

10, we completed a $150,000 investment in 100,000 shares of Series D Preferred Stock as well as 200,000 shares of Series C Preferred

Stock. Orbital Tracking is an OTC BB listed company. It provides satellite based tracking, services as well as mobile voice and

data communications services globally via satellite to the commercial and government users. Orbital specializes in services

related to the Globalstar satellite constellation, including ground station construction, simplex tracking services and satellite

telecommunications voice airtime. Orbital operates various e-commerce retail and tracking portals where users around the world

can purchase satellite hardware and track assets in real-time on mobile devices or PCs. Each share of Series C Preferred Stock

converts into 10 shares of Common Stock. Each share of Series D Preferred Stock converts into 5 shares of Common Stock.

Vapor Corp. (VPCO) On November 17,

2014, we completed an investment in 7% Convertible Notes and Warrants. Vapor, a Nasdaq Capital Markets listed company, designs,

markets and distributes electronic cigarettes, vaporizers, e-liquids and accessories. Vapor represents our first diversification

into an industry that we believe has exciting growth potential.

Optex Systems, Inc. (OPXS) On November

18, 2014, we completed an investment in two year 12% Convertible Senior Notes. Optex, an OTC QB listed company, has been in business

for 17 years and qualifies for the preference the DoD grants in its small business vendor program. Optex supplies periscopes,

sighting systems and other products to defense contractors and militaries. Optex purchased the assets of another company in the

industry. Optex plans to acquire a business that sells non-glare coatings for military applications and binoculars commercially.

Grand Avenue, 5 Patriot Center, Fl. 2 Englewood, NJ 07631 O: (201)408-5126 F: (201)408.5125

Actinium Pharmaceuticals, Inc. (ATNM) On

February 6, 2015 we completed an investment in shares of common stock and warrants. Actinium develops oncology drugs. Actinium

co-developed with Memorial Sloan Kettering the patented Alpha Particle Immunotherapy Technology. Actinium has a drug preparing

for a Phase III trial and another in Phase I/II clinical trials.

datchat. (Private) On February 6, 2015

we completed an investment in common stock. datchat provides patent pending secret encrypted self-destructing messages in photos

and videos, allows customers to conceal secret messages and pictures in plain sight and prevents screen shots of your photos and

messages. In addition to capital we are working closely with the company. Point owns approximately 12% of the company. We hope

to see this company complete an exit strategy through sale or public offering in the second half of 2015

Pulmatrix Inc. (now RTGN) On February

13, 2015 we invested in a 5% loan to the company. Pulmatrix is developing a dry powder for inhaled therapeutics. On March 16,

2015 Pulmatrix announced a merger with Ruthigen, Inc. a NASDAQ publicly traded company in which Point Capital had a previous investment.

Pershing Gold Corporation (PGLC). On

March 27, 2015 we completed an investment in the company for shares of common stock and warrants. Pershing Gold explores, develops

and mines gold and precious metals primarily in Nevada.

MabVax Therapeutics Holdings, Inc. (MBVX).

On April 5, 2015 we completed an investment in shares of common stock and warrants. MabVax engages in the discovery, development

and commercialization of human monoclonal cancer vaccines under exclusive license from Memorial Sloan-Kettering. MabVax has achieved

full enrollment for two of its Phase II clinical trials. A vaccine for an orphan disease will be ready for a Phase II trial in

H2 2015. MabVax entered into an agreement with Juno Therapeutics.

Grand Avenue, 5 Patriot Center, Fl. 2 Englewood, NJ 07631 O: (201)408-5126 F: (201)408.5125